The management of treatment resistant schizophrenia does remain controversial [48] but guidelines have some consistency in supporting use of clozapine [49,50] and psychosocial approaches for which ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Background: Therapeutic options for patients with treatment-resistant schizophrenia are limited, and combination treatment with atypical antipsychotic drugs is an often used strategy. We tested ...

There are a few unmet needs in schizophrenia that can make a big difference in the prognosis and quality of life of patients. Treatment adherence is a big challenge for patients with schizophrenia ...

Schizophrenia may be misdiagnosed as depression or bipolar disorder, which delays treatment and negatively impacts the prognosis, explained Megan Ehret, PharmD, MS, BCPP, of the University of ...

serotonergic and adrenergic receptors – failed to improve the positive and negative schizophrenia symptom scale (PANSS) compared to conventional therapy in patients with treatment-resistant ...

a second-generation antipsychotic often used for treatment-resistant schizophrenia, also ranked low (0.12). For reference, a significant or noticeable SMD result would be anything 0.5 or higher ...

Johnson & Johnson (NYSE: JNJ) announced today that 23 abstracts featuring new real-world and clinical trial data from across its neuropsychiatry portfolio and pipeline will be presented at the annual ...

While Cobenfy’s approval marks a significant step forward in schizophrenia treatment, questions remain about its long-term impact, particularly in addressing cognitive symptoms and its potential ...

Auditory verbal hallucinations are one of the hallmarks of psychosis, particularly in people with schizophrenia, which affects 24 million people globally. These voices often bully or abuse the ...

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers Squibb’s schizophrenia treatment Cobenfy (KarXT) has had an unusual ...

Most kids with attention issues won't go on to develop serious psychiatric conditions like psychosis or schizophrenia ... in adults who undergo the same treatment, a large, NIH-funded study.